Filter Results
:
(594)
Show Results For
-
All HBS Web
(1,029)
- People (4)
- News (252)
- Research (594)
- Events (7)
- Multimedia (25)
- Faculty Publications (383)
Show Results For
-
All HBS Web
(1,029)
- People (4)
- News (252)
- Research (594)
- Events (7)
- Multimedia (25)
- Faculty Publications (383)
←
Page 30 of
594
Results
Sort by
- 22 Aug 2006
- First Look
First Look: August 22, 2006
805-067 Molecular Insight has developed a novel biopharmaceutical to detect heart attacks. The company's unique approach to intellectual property protection uses the Hatch Waxman Act and the Orphan Drug Act. The company is struggling to...
View Details
Keywords:
Martha Lagace
- 17 Sep 2001
- Research & Ideas
Why E-commerce Didn’t Die With the Fall of Webvan
drugs for chronic conditions—from pharmacies to a combination of direct mail and telephone. The idea was that if you have a chronic condition, you're in a replenishment mode. You have to fill the prescription regularly over a number of...
View Details
- 15 Apr 2014
- First Look
First Look: April 15
from the U.S. Food and Drug Administration (FDA) ordering the company to halt the sale and promotion of its genetic testing kit. The FDA stated that the product was marketed as a diagnostic and preventative tool and that it was subject to...
View Details
Keywords:
Sean Silverthorne
- 25 Feb 2014
- First Look
First Look: February 25
is based in Massachusetts and lists in London on AIM. Products are genetically modified fast-growing salmon for fish farmers and disease-prevention drugs and diagnostic kits for farmed shrimp. Purchase this case:...
View Details
Keywords:
Sean Silverthorne
- 01 Jul 2008
- First Look
First Look: July 1, 2008
establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel to its effort to develop anti-aging therapeutics? And, should it in-license a second drug development candidate? Purchase...
View Details
Keywords:
Martha Lagace
- 13 Sep 2011
- First Look
First Look: September 13
come primarily from the non-drug treatment (87.4% and 70.2% respectively), whereas gains from detailing come at the expense of competing drugs (84%). By contrast, the random coefficient logit model predicts that gains from DTCA, M&E,...
View Details
Keywords:
Sean Silverthorne
- 18 Sep 2007
- First Look
First Look: September 18, 2007
http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=907025 NatuRi Corporation Harvard Business School Case 807-027 NatuRi Corporation was a start up, founded in 2005, aiming to manufacture a cholesterol-lowering drug made from...
View Details
Keywords:
Martha Lagace
- 12 Feb 2008
- First Look
First Look: February 12, 2007
stake of 9.5% in Ligand Pharmaceuticals, Inc., a specialty pharmaceutical company. Third Point believed that Ligand had a strong drug portfolio and pipeline but that it was highly undervalued due to poor management. After gaining board...
View Details
Keywords:
Martha Lagace
- 21 Apr 2009
- First Look
First Look: April 21, 2009
Industry Location Author:Arthur A. Daemmrich Abstract A consumer-oriented model for drug development and use has attracted attention in recent years as an alternative to the much-maligned approach of mass-marketing blockbuster drugs. In a...
View Details
Keywords:
Martha Lagace
- ←
- 30